Clinical

Phase 1b study of a new anti-VEFG antibody has reported BCVA gains across wet AMD, diabetic macular edema and retinal vein occlusion

A brief clinical update reporting on a new anti-VEGF antibody conjugate polymer (identified as KSI-301) has highlighted visual acuity gains with three indications – wet… Read More »Phase 1b study of a new anti-VEFG antibody has reported BCVA gains across wet AMD, diabetic macular edema and retinal vein occlusion

Real world data has reported the comparison outcomes between ranibizumab (Lucentis) and aflibercept (Eylea) for Diabetic Macular Edema (DME)

A clinical research report, published in the journal Ophthalmology, has found that two leading anti-VEGF treatments had shown beneficial outcomes for DME in a study… Read More »Real world data has reported the comparison outcomes between ranibizumab (Lucentis) and aflibercept (Eylea) for Diabetic Macular Edema (DME)